Annual Health Care Conference | SilverScorpio.Com

Humana Inc. to Present at the Cowen and Company 30th Annual Health Care Conference

March 5, 2010 By vani Leave a Comment

LOUISVILLE, Ky.–(Business Wire)–
Humana Inc. (NYSE: HUM) announced today that James H. Bloem, senior vice
president, chief financial officer and treasurer, will make a presentation to
investors at the Cowen and Company 30th Annual Health Care Conference on
Tuesday, March 9, 2010, at 3:45 p.m. eastern time.

A live audio Web cast of the presentation along with the accompanying slides
will be available via Humana`s Investor Relations page at www.humana.com. The
company suggests Web cast participants sign on approximately 15 minutes in
advance of the presentation to allow time to run a system test and download any
free software needed for access purposes.

Humana Inc., headquartered in Louisville, Kentucky, is one of the nation`s
largest publicly traded health and supplemental benefits companies, with
approximately 10.3 million medical members and approximately 7.2 million
specialty-benefit members. Humana is a full-service benefits solutions company,
offering a wide array of health and supplemental benefit plans for employer
groups, government programs and individuals.

Over its 49-year history, Humana has consistently seized opportunities to meet
changing customer needs. Today, the company is a leader in consumer engagement,
providing guidance that leads to lower costs and a better health plan experience
throughout its diversified customer portfolio.

More information regarding Humana is available to investors via the Investor
Relations page of the company`s web site at www.humana.com, including copies
of:

* Annual reports to stockholders;
* Securities and Exchange Commission filings;
* Most recent investor conference presentations;
* Quarterly earnings news releases;
* Replays of most recent earnings release conference calls;
* Calendar of events (including upcoming earnings conference call dates and
times, as well as planned interaction with research analysts and institutional
investors);
* Corporate Governance information.

Humana Inc.
Investor Relations:
Regina Nethery, 502-580-3644
Rnethery@humana.com
or
Corporate Communications:
Tom Noland, 502-580-3674
Tnoland@humana.com

Filed Under: International News Tagged With: Annual Health Care Conference, Benefit Members, Benefit Plans, Cowen And Company, Customer Portfolio, Diversified Customer, earnings conference, Earnings News, Earnings Release Conference, Employer Groups, Health Care Conference, Humana Inc, institutional investors, Investor Conference, Medical Members, Plan Experience, Quarterly Earnings, securities and exchange commission, Supplemental Benefit, Supplemental Benefits

Idera Pharmaceuticals to Present at Cowen and Company 30th Annual Health Care Conference

March 5, 2010 By vani Leave a Comment

CAMBRIDGE, Mass.–(Business Wire)–
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in
the discovery and development of DNA- and RNA-based drug candidates targeted to
Toll-like Receptors (TLR), today announced that it will discuss its drug
discovery and development programs and provide a general corporate overview at
the Cowen and Company 30th Annual Health Care Conference on Tuesday, March 9, at
3:00 p.m. EST at the Boston Marriott Copley Place in Boston, MA.

The presentation will be available via live audio webcast on the Company`s
website at www.iderapharma.com. Archived replays will also be located on the
Company`s site following the events. The presentation date and time is subject
to change. The most up to date information will be available on the Company`s
website.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals develops drug candidates to treat infectious diseases,
autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for
use as vaccine adjuvants. Our proprietary drug candidates are designed to
modulate specific Toll-like Receptors, which are a family of immune system
receptors that direct immune system responses. Our pioneering DNA and RNA
chemistry expertise enables us to create drug candidates for internal
development and generates opportunities for multiple collaborative alliances.
For more information, visit www.iderapharma.com.

Idera Forward Looking Statements

This press release contains forward-looking statements concerning Idera
Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For this
purpose, any statements contained herein that are not statements of historical
fact may be deemed to be forward-looking statements. Without limiting the
foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “estimates,”
“intends,” “should,” “could,” “will,” “may,” and similar expressions are
intended to identify forward-looking statements. There are a number of important
factors that could cause the Company`s actual results to differ materially from
those indicated by such forward-looking statements, including whether products
based on the Company`s technology will advance into or through the clinical
trial process on a timely basis or at all and receive approval from the United
States Food and Drug Administration or equivalent foreign regulatory agencies;
whether, if the Company`s products receive approval, they will be successfully
distributed and marketed; whether the Company`s cash resources will be
sufficient to fund the its operations; and such other important factors as are
set forth under the caption “Risk Factors” in the Company`s Quarterly Report on
Form 10-Q for the three months ended September 30, 2009, which important factors
are incorporated herein by reference. The Company disclaims any intention or
obligation to update any forward-looking statements.

Idera Pharmaceuticals, Inc.
Kelly Luethje, 617-679-5519
kluethje@iderapharma.com
or
MacDougall Biomedical Communications
Chris Erdman, 781-235-3060
cerdman@macbiocom.com

Filed Under: International News Tagged With: Annual Health Care Conference, Audio Webcast, Biotechnology Company, Boston Marriott Copley, Boston Marriott Copley Place, Collaborative Alliances, Conference Cambridge, Copley Place In Boston, Cowen And Company, Dna And Rna, drug discovery and development, Health Care Conference, Idera Pharmaceuticals Inc, Immune System Responses, inflammatory diseases, Marriott Copley Place, respiratory diseases, Rna Chemistry, Toll Like Receptors, Vaccine Adjuvants

BioDelivery Sciences to Present at the Cowen and Company 30th Annual Health Care ConferenceBioDelivery Sciences to Present at the Cowen and Company 30th Annual Health Care Conference

March 5, 2010 By vani Leave a Comment

RALEIGH, N.C.–(Business Wire)–
BioDelivery Sciences International, Inc. (Nasdaq:BDSI) announced today that Dr.
Mark A. Sirgo, President and Chief Executive Officer, will present at the Cowen
and Company 30th Annual Health Care Conference in Boston on Wednesday, March 10
at 8:00 AM Eastern Time.

Dr. Sirgo will discuss BDSI`s product portfolio, including BEMA Buprenorphine
for pain and opioid dependence, BEMA Granisetron for nausea and vomiting, and
the commercial launch of ONSOLIS (fentanyl buccal soluble film). Dr. Sirgo will
also discuss anticipated Company milestones for 2010.

The presentation will be webcast live and can be accessed at www.bdsi.com. For
those who are not available to listen to the live broadcast, the presentation
will be archived.

About BioDelivery Sciences International

BioDelivery Sciences (NASDAQ:BDSI) is a specialty pharmaceutical company that is
leveraging its novel and proprietary patented drug delivery technologies to
develop and commercialize, either on its own or in partnerships with third
parties, new applications of proven therapeutics. BDSI is focusing on developing
products to meet unmet patient needs in the areas of pain management and
oncology supportive care. BDSI`s pain franchise currently consists of two
products utilizing the Company`s patented BEMA buccal soluble film technology.
ONSOLIS (fentanyl buccal soluble film) was approved by FDA on July 16, 2009, for
the management of breakthrough pain in patients with cancer, eighteen years of
age and older, who are already receiving and who are tolerant to opioid therapy
for their underlying persistent cancer pain. The commercial rights to ONSOLIS
are licensed to Meda AB. Our second pain product, BEMA Buprenorphine, is in
Phase 2 clinical development for the treatment of chronic pain, and in a higher
dose formulation for the treatment of opioid dependence. Additional product
candidates are being developed utilizing the BEMA technology for conditions such
as nausea/vomiting (BEMA Granisetron) and migraine (BEMA “Triptan”). The Company
is also working with its patented Bioral cochleate technology to facilitate oral
dosing of drugs that would otherwise require intravenous administration. The
first product under development using the technology is Bioral Amphotericin B.
The Company`s headquarters is located in Raleigh, North Carolina. For more
information please visit www.bdsi.com.

BDSI®, BEMA® and Bioral® are registered trademarks of BioDelivery Sciences
International, Inc. ONSOLIS® is a registered trademark of Meda Pharmaceuticals,
Inc.

Cautionary Note on Forward-Looking Statements

This press release and the statements of representatives and partners of
BioDelivery Sciences International, Inc. (the “Company”) related thereto
contain, or may contain, among other things, certain “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve significant risks and
uncertainties. Such statements may include, without limitation, statements with
respect to the Company`s plans, objectives, projections, expectations and
intentions and other statements identified by words such as “projects,” “may,”
“could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,”
“intends,” “plans,” or similar expressions. These statements are based upon the
current beliefs and expectations of the Company`s management and are subject to
significant risks and uncertainties, including those detailed in the Company`s
filings with the Securities and Exchange Commission. Actual results may differ
significantly from those set forth in the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties that are
subject to change based on various factors (many of which are beyond the
Company`s control).

ICR, Inc.
Donald Ellis
925-253-1240
donald.ellis@icrinc.com
or
BioDelivery Sciences International, Inc.
Al Medwar
Vice President, Marketing and Corporate Development
919-582-9050
amedwar@bdsinternational.com

Filed Under: International News Tagged With: Annual Health Care Conference, Bdsi, Biodelivery Sciences International, Biodelivery Sciences International Inc, breakthrough pain, Buprenorphine, chief executive officer, Company Milestones, Cowen And Company, Developing Products, Drug Delivery Technologies, Fentanyl, Film Technology, Granisetron, Health Care Conference, launch, live broadcast, Nausea And Vomiting, Persistent Cancer Pain, Sciences International Inc

Open-Source Functional Testing Tool for Adobe Flex Applications – New and

March 5, 2010 By vani Leave a Comment

The presentation will be webcast live and can be accessed at www.bdsi.com. For
those who are not available to listen to the live broadcast, the presentation
will be archived.

About BioDelivery Sciences International

BDSI®, BEMA® and Bioral® are registered trademarks of BioDelivery Sciences
International, Inc. ONSOLIS® is a registered trademark of Meda Pharmaceuticals,
Inc.

Cautionary Note on Forward-Looking Statements

Filed Under: International News Tagged With: Annual Health Care Conference, Bdsi, Biodelivery Sciences International, Biodelivery Sciences International Inc, breakthrough pain, Buprenorphine, chief executive officer, Company Milestones, Cowen And Company, Drug Delivery Technologies, Film Technology, Functional Testing, Granisetron, Health Care Conference, live broadcast, Nausea And Vomiting, Persistent Cancer Pain, Product Candidates, Sciences International Inc, Testing Tool

Humana Inc. to Present at the Cowen and Company 30th Annual Health Care Conference

Idera Pharmaceuticals to Present at Cowen and Company 30th Annual Health Care Conference

BioDelivery Sciences to Present at the Cowen and Company 30th Annual Health Care ConferenceBioDelivery Sciences to Present at the Cowen and Company 30th Annual Health Care Conference

Open-Source Functional Testing Tool for Adobe Flex Applications – New and

Search More News

Technology News

Ads